For UK HealthTech companies
Your healthtech solution works, the NHS procurement process does not
Complex approval pathways, risk-averse committees, and cost-over-value frameworks mean genuinely effective solutions can spend years in limbo before reaching a single patient.
Two minutes. Solva follows up with specific procurement navigation options.
- Healthtech companies investing significant resources into pilot projects that do not convert into widespread adoption
- Innovative solutions remaining on the sidelines while the NHS struggles with inefficiencies that could be addressed
- Frustrated sales teams facing repeated rejections or indefinite delays despite clear clinical value
- Competitors from other markets gaining traction due to more streamlined procurement processes elsewhere
- Increased operational overhead due to extended sales cycles
- Diversion of R&D resources to adapt solutions for specific NHS trust requirements
- Significant revenue loss from missed market opportunities
- Increased burn rate for startups due to prolonged time-to-market
- Perception of being unable to penetrate the UK's largest healthcare provider
- Difficulty attracting top talent who seek to make a tangible impact
Three in ten HealthTech companies chose not to bid on an NHS tender in 2024 due to the perceived burden of the procurement system (ABHI, 2024)
Source: https://www.abhi.org.uk/media/fvhmxqbi/2024-pulse-of-healthtech-survey.pdf
Frequently asked questions
Why does this problem persist?
The NHS procurement process is often complex, protracted, and heavily focused on cost optimization rather than value or innovation. This creates significant barriers for healthtech companies, especially SMEs, to get their solutions onto approved frameworks.
What is the cost of leaving it unaddressed?
No verified UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.